Drug intelligence / Profile preview

PRM-125

Development stage: Discontinued
Lead developer: Phoenix Rising Management
Administration: Oral

Overview

PRM-125 is an experimental drug that was developed for the treatment of hypertension. It was initially developed by Phoenix Rising Management and later associated with PRM Pharma. The drug reached Phase 3 clinical trials, where it was evaluated as a once-daily oral therapy to reduce ambulatory blood pressure in adults with primary hypertension. However, development has been discontinued and no further clinical activity is ongoing. The precise mechanism of action for PRM-125 remains unknown, and there are no approved indications or known adverse events reported in public sources[1][2][3].

Beyond the preview

Go deeper on PRM-125.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PRM-125.

Explore the full profile